ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vapendavir

Also written as “Vapendavir”, “VPV 1000 mg” and “vapendavir 132 mg capsule”.

Its studies are mostly in Enterovirus Infections · Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Tract Infections, led by 3 companies.

Drug pageVapendavir: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Oct 11, 202310 company-led studies, 1 open or runningNext primary completion: Nov 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Altesa Biosciences41 open or runningphase 2since Oct 11, 2023Jun 7, 2023Nov 15, 2027phase 2 · NCT07610395
Vaxartits history only40 open or runningphase 2since Feb 13, 2015Mar 24, 2014none ahead
Biota Scientific Management Ptyits history only20 open or runningphase 2since Aug 3, 2010Aug 3, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Altesa Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 7, 2023First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05962645 · 21 enrolled · United States
  2. Oct 11, 2023Phase 2 study in Virus DiseasesNCT06149494 · 52 enrolled · United Kingdom
  3. Feb 11, 2025Phase 2 study in Healthy MalesNCT06834295 · 8 enrolled · United Kingdom
  4. May 12, 2026Phase 2 study in Rhinovirus InfectionNCT07610395 · 180 planned · United States, United Kingdom

Ahead

  1. Nov 15, 2027Primary completion: phase 2 study in Rhinovirus InfectionNCT07610395

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“VP1 capsid protein inhibitor”ChEMBL 37, by rule

Studies

All 4 Altesa Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07610395Rhinovirus Infection · United States, United Kingdom2RecruitingNov 15, 2027180
NCT06834295Healthy Males · United Kingdom2CompletedMar 23, 20258
NCT06149494Virus Diseases · United Kingdom2CompletedMar 30, 202552
NCT05962645Pulmonary Disease, Chronic Obstructive · United States1CompletedDec 12, 202321

How it is read

Names in the registry

  • “Vapendavir”, 6 entries
  • “VPV 1000 mg”, 1 entry
  • “vapendavir 132 mg capsule”, 1 entry
  • “vapendavir 264 mg tablet”, 1 entry
  • “vapendavir 24 mg/mL oral suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.